ClinicalTrials.gg
CompletedNCT06908642Updated Dec 9, 2025

Evaluation the Safety of hemay005 Tablets

A Phase 1 interventional study of Hemay005 tablet and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Anhui Hemay Pharmaceutical Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-09.

Sponsored by Anhui Hemay Pharmaceutical Co., Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
468
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China — 108 open to participants now, 125 under way, 15 of them phase 3. Pulmonary Disease, Chronic Obstructive · China.

Enrollment
72nd of 286
468 · median 155
Started
2024
with 33 others
Phase 1
28 of 404
4 open now
Registered
324th of 404
by date

Among the 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China, this one is the 72nd largest by enrollment of the 286 interventional ones that give a count, is one of 34 that started in 2024, is one of 28 in phase 1, and was the 324th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

108 of the 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China are open now. Recruiting first, the newest first:

103 more — sign in →

All 108 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China, or all of them as a file.
02

Study summary

Explore the influence of different administration methods (titration/non-titration) of Hemay005 tablets on the incidence of adverse reactions.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1) Male and female subjects aged 18 to 65 years old (inclusive of 18 and 65);
  • 2) Weight: Male should be no less than 50.0 kg, female no less than 45.0 kg. (BMI) [ = weight (kg) / height2 (m2) ] should be within the range of 18.5 to 30.0 kg/m2 (inclusive of boundary values);
  • 3) Before the trial, they have been thoroughly informed about the nature, significance, possible benefits, as well as possible inconveniences and potential risks of the trial, and have voluntarily participated in this clinical trial. They can communicate well with the researchers, comply with all requirements of the entire study, and have signed a written form.

Exclusion criteria

Exclusion Criteria:

  • 1) Participants who have participated in other drug/medical device trials within the previous 3 months (based on the use of the trial drugs/medical devices);
  • 2) Those with clinical manifestations of abnormalities that need to be excluded, including but not limited to diseases in the nervous system, cardiovascular system, hematological and lymphatic system, immune system, kidneys, liver, gastrointestinal tract, respiratory system, metabolism and bone system;
  • 3) Those with specific allergy histories (asthma, urticaria, eczema, etc.), or with allergic constitution (such as those allergic to two or more drugs, foods or pollen), or those known to be allergic to this product;
  • 4) Participants who have lost or donated blood exceeding 400ml within the previous 3 months, or those who plan to donate blood during the trial;
  • 5) Pregnant or lactating women, or those who have a fertility plan or donation plan for sperm or eggs within two weeks before the trial or within 3 months after the last administration, and are unwilling or have not taken effective measures;
  • 6) General physical examination, vital signs, laboratory tests (blood routine, blood biochemistry, coagulation function, urine routine, and C, AIDS, syphilis, and tests, pregnancy test for females, etc.) within the previous 7 days before randomization; results within the previous 14 days before randomization judged by clinical doctors as abnormal with clinical significance; chest X-ray results within the previous 3 months before randomization judged by clinical doctors as abnormal with clinical significance;
  • 7) Alcohol breath test results greater than 0.0mg/100ml or positive results in drug abuse screening;
  • 8) Those who have a history of severe vomiting or diarrhea within the previous 7 days or any other diseases or physiological conditions that may interfere with the test results;
  • 9) Those who have suffered from major clinical diseases or undergone major surgical operations within 3 months before screening;
  • 10) Those who consume more than 14 units of alcohol per week (1 unit = 17.7 mL ethanol, which is equivalent to 357 mL of 5% alcohol beverage, 43 mL of 40% alcohol liquor, or 147 mL of 12% wine) within 3 months before screening, or those who cannot abstain from alcohol during the test;
  • 11) Those who smoke more than 5 cigarettes per day on average within 3 months before screening, or those who cannot stop using any tobacco products during the test;
  • 12) Those who consume excessive tea, coffee and/or beverages rich in caffeine (more than 8 cups, 1 cup = 250 mL) every day within 3 months before screening.
  • 13) Exclude those who have used any drugs that inhibit or induce liver drug-metabolizing enzymes within the past 30 days (such as inducers - barbiturates, carbamazepine, phenytoin, ; inhibitors - SSRI class antidepressants, cimetidine, sedative-hypnotics, verapamil, fluoroquinolones, antihistamines).
  • 14) Those with a history of tuberculosis or those with active tuberculosis during the screening period;
  • 15) Those who are unable to eat or have difficulty swallowing;
  • 16) Those who have used any prescription drugs, over-the-counter drugs, health supplements, herbal products or vaccines within 14 days before randomization or have stopped taking them for less than 5 half-lives;
  • 17) Those who have used Apremilast or Hemay005 tablets in the past;
  • 18) Those who cannot tolerate venipuncture and/or have a history of fainting or needle shock;
  • 19) Those who have used any drugs within one year before screening;
  • 20) Those who, in the researcher's opinion, have poor compliance or any factors that make them unsuitable to participate in this trial.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
468 participants (actual)

Study arms

  • Active comparator
    0-45mg Hemay005

    By using titration method, the dosage of the drug was gradually increased from 0 to 45 mg BID for 14 days

    Drug: Hemay005 tablet

  • Active comparator
    45mg Hemay005

    The subjects took the medicine twice a day, 45 mg each time, for 14 days.

    Drug: Hemay005 tablet

  • Active comparator
    0-60mg Hemay005

    By using titration method, the dosage of the drug was gradually increased from 0 to 60 mg BID for 14 days

    Drug: Hemay005 tablet

  • Active comparator
    60mg Hemay005

    The subjects took the medicine twice a day, 60 mg each time, for 14 days.

    Drug: Hemay005 tablet

  • Active comparator
    0-75 mg Hemay005

    By using titration method, the dosage of the drug was gradually increased from 0 to 75 mg BID for 14 days

    Drug: Hemay005 tablet

  • Active comparator
    75 mg Hemay005

    The subjects took the medicine twice a day, 75 mg each time, for 14 days.

    Drug: Hemay005 tablet

  • Placebo comparator
    placebo

    The subjects took the medicine twice a day. In the first week, they took placebos; in the second week, they took 60 mg hemay005 each time, for a total of 14 days of medication.

    Drug: Placebo

Interventions

  • Hemay005 is a small molecule PDE4 inhibitor.

  • DrugPlacebo

    Placebos are the same as drugs, but contain no Hemay005.

06

What researchers measure

Primary outcomes

  1. Explore the influence of different administration methods (titration/non-titration) of Hemay005 tablets on the incidence of adverse reactions.

    Number of Participants With Treatment-Related Adverse Events as Assessed by Grade of Adverse Event

    Time frame: 14 Days

07

Study locations

1 site
  • The Second Affiliated Hospital of Wannan Medical College
    Wuhu, Anhui 241000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Jun 2025, 5 months.

Of 158 industry-sponsored phase 1 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's 5 months is above that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 2 and three quarters within 11.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2025
First posted
Apr 3, 2025
StartActual
Dec 25, 2024
Primary completionActual
Jun 3, 2025
CompletionActual
Jun 3, 2025
Last update
Dec 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06908642
Lead sponsor
Anhui Hemay Pharmaceutical Co., Ltd
Responsible party
Sponsor
First posted
Apr 3, 2025
Start date
Dec 25, 2024
Primary completion
Jun 3, 2025
Completion
Jun 3, 2025
Last update
Dec 9, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hemay005

Start the discussion